194 related articles for article (PubMed ID: 28747053)
1. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
Vera I; Júdez FJ
Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
[TBL] [Abstract][Full Text] [Related]
2. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
3. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
4. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
5. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM
Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
9. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
10. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Özdener AE; Rivkin A
Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
[TBL] [Abstract][Full Text] [Related]
12. ▼ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
[TBL] [Abstract][Full Text] [Related]
13. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
Brenner DM; Sayuk GS; Abel JL; Burslem K
J Manag Care Spec Pharm; 2021 Apr; 27(4):469-477. PubMed ID: 33769858
[No Abstract] [Full Text] [Related]
14. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
Chey WD; Dove LS; Andrae DA; Covington PS
Aliment Pharmacol Ther; 2017 May; 45(10):1319-1328. PubMed ID: 28326568
[TBL] [Abstract][Full Text] [Related]
15. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
16. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
17. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.
Abel JL; Carson RT; Andrae DA
Qual Life Res; 2019 Feb; 28(2):369-377. PubMed ID: 30267294
[TBL] [Abstract][Full Text] [Related]
18. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
19. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
20. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
